Moleculin Biotech Inc MBRX Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$8.70 down $0.03, 0.34% at close Nov 6
Last close · Previous close $8.73
- Market cap
- $2.32MAt the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$8.70down $0.21, 2.36%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$8.73Nov 5
- Volume14.28KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume42.80KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $3.23 to $253.05; now $8.70
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
MBRX beat the S&P 500 in 2 of 7 periods.
| Period | MBRX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | MBRX: down 2.4% S&P 500: down 5.6% | MBRX beat the S&P 500 by 3.2 percentage points Beat |
| 3M | MBRX: up 13.0% S&P 500: down 4.1% | MBRX beat the S&P 500 by 17.1 percentage points Beat |
| YTD | MBRX: down 86.9% S&P 500: up 8.7% | MBRX trailed the S&P 500 by 95.6 percentage points Trailed |
| 1Y | MBRX: down 96.2% S&P 500: up 10.9% | MBRX trailed the S&P 500 by 107.1 percentage points Trailed |
| Long term | ||
| 3Y | MBRX: down 99.8% S&P 500: up 75.0% −87.5% vs +20.5% a year | MBRX trailed the S&P 500 by 174.8 percentage points Trailed |
| 5Y | MBRX: down 100.0% S&P 500: up 67.8% −78.6% vs +10.9% a year | MBRX trailed the S&P 500 by 167.8 percentage points Trailed |
| 10Y | MBRX: down 100.0% S&P 500: up 313.1% −62.0% vs +15.2% a year | MBRX trailed the S&P 500 by 413.1 percentage points Trailed |
$10,000 invested in MBRX 10 years ago (Nov 4, 2016) would be worth about $1 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
MBRX beat the S&P 500 in 2 of 7 periods.
| Period | MBRX and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | MBRX: down 2.4% S&P 500: down 5.6% | MBRX beat the S&P 500 by 3.2 percentage points Beat |
| 3M | MBRX: up 13.0% S&P 500: down 4.3% | MBRX beat the S&P 500 by 17.3 percentage points Beat |
| YTD | MBRX: down 86.9% S&P 500: up 7.8% | MBRX trailed the S&P 500 by 94.7 percentage points Trailed |
| 1Y | MBRX: down 96.2% S&P 500: up 9.7% | MBRX trailed the S&P 500 by 105.9 percentage points Trailed |
| Long term | ||
| 3Y | MBRX: down 99.8% S&P 500: up 68.8% −87.5% vs +19.1% a year | MBRX trailed the S&P 500 by 168.6 percentage points Trailed |
| 5Y | MBRX: down 100.0% S&P 500: up 56.9% −78.6% vs +9.4% a year | MBRX trailed the S&P 500 by 156.9 percentage points Trailed |
| 10Y | MBRX: down 100.0% S&P 500: up 252.6% −62.0% vs +13.4% a year | MBRX trailed the S&P 500 by 352.6 percentage points Trailed |
$10,000 invested in MBRX 10 years ago (Nov 4, 2016) would be worth about $1 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$400,500.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Jun 2, 2016.
Stock splits
4
Latest: 1-for-20 on . Share counts adjust after each split.
All 4 splits
- 1-for-20
- 1-for-25
- 1-for-15
- 1-for-6
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
Other valuation measures
- Price-to-bookPausedBook value as of Jun 30, 2026
See the note under the price. - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - −1,092.35%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - −$4.79MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own MBRX DCF in Excel. Value Moleculin Biotech with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$30.33M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$7.02M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$6.58M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$5.90M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$17.81M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$25.40M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $0.00 | $15.55M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$12.85M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$7.64M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $0.00 | −$15.89M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $0.00 | −$29.03M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $0.00 | −$29.77M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $0.00 | −$26.05M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $0.00 | −$33.56M | Paused See the note under the price. |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$25.36MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$25.36MLast 12 months
- Capital spending$0.00Last 12 months
Shareholder returns
- $25.10MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $7.26MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$147.00KAs of Jun 30, 2026
- Net cash$7.12MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 0.94As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.01As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −816.6%Last 12 months
Over the last 12 months, Moleculin Biotech lost money: its net loss was 816.6% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −139.5%Last 12 months
Over the last 12 months, Moleculin Biotech’s net loss was 139.5% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Moleculin Biotech Inc
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B /2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents. Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Texas, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
MBRX news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
MBRX stock FAQ
What is MBRX stock’s price today?
Moleculin Biotech (MBRX) traded at $8.70 at the close on , down $0.03 (0.34%) from the previous close of $8.73. Over the past 52 weeks it has traded between $3.23 and $253.05.
If you invested $1,000 in MBRX 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in MBRX on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $0 if invested five years ago and $38 if invested one year ago. Past performance doesn’t predict future returns.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market capitalization is about $2.3 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $8.70 (how market cap works).
Does MBRX pay a dividend?
Moleculin Biotech hasn’t paid a dividend in the last twelve months.
What is MBRX’s 52-week high and low?
Over the past 52 weeks MBRX has traded as low as $3.23 and as high as $253.05. At $8.70 at the close on , it is 96.6% below that high and 169.5% above the low.
What is MBRX’s all-time high?
MBRX’s highest closing price was $400,500.00 on , adjusted for stock splits. At $8.70 at the close on , it is 100.0% below that record.
Has MBRX stock ever split?
Yes, four times: 1-for-6 on ; 1-for-15 on ; 1-for-25 on ; 1-for-20 on .
How has MBRX stock performed?
Including dividends and measured to the close on , MBRX has returned −86.9% so far this year and −96.2% over the past year, and −100.0% over five years (−78.6% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Moleculin Biotech in?
Moleculin Biotech is in the Healthcare sector and the Biotechnology industry, and is headquartered in Texas, USA.
What exchange does MBRX trade on?
Moleculin Biotech trades on the Nasdaq under the ticker symbol MBRX. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.